OncoMatch/Clinical Trials/NCT06457503
A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
Is NCT06457503 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies multiple treatments including Toripalimab and Cisplatin for nasopharyngeal cancer recurrent.
Treatment: Toripalimab · Cisplatin · Gemcitabine · Carboplatin — This study aims to investigate toripalimab with chemotherapy in participants with nasopharyngeal cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage IV-B
Metastatic disease required
Demographics
Prior therapy
Cannot have received: systemic therapy
Exception: no prior systemic therapy in the recurrent or metastatic setting
Prior systemic therapy administered in the recurrent or metastatic setting
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Arkansas for Medical Sciences · Little Rock, Arkansas
- University of California, Irvine · Irvine, California
- University of California, San Francisco · San Francisco, California
- Emory Winship Cancer Institute · Atlanta, Georgia
- Boston Medical Center · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06457503 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage IV-B is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages